Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Forte Biosciences, Inc. (FBRX : NSDQ)

• Company Description    Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $11.45 Daily Weekly Monthly 20 Day Moving Average: 182,669 shares Shares Outstanding: 6.58 (millions) Market Capitalization: $75.41 (millions) Beta: 2.97 52 Week High: $28.68 52 Week Low: $4.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.65% -12.07% 12 Week 56.06% 31.27% Year To Date -49.56% -52.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3060 PEGASUS PARK DRIVE BUILDING 6 - DALLAS,TX 75247 USA ph: 310-618-6994 fax: - investors@fortebiorx.com http://www.fortebiorx.com

• General Corporate Information    Officers Paul A. Wagner - Chairman and Chief Executive Officer Antony Riley - Chief Financial Officer Scott Brun - Director Barbara K. Finck - Director David Gryska - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 34962G208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 6.58 Most Recent Split Date: 8.00 (0.04:1) Beta: 2.97 Market Capitalization: $75.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 65.75% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -149.15 12/31/24 - -132.02 ROA 06/30/25 - - 03/31/25 - -114.25 12/31/24 - -103.13 Current Ratio 06/30/25 - - 03/31/25 - 5.22 12/31/24 - 6.76 Quick Ratio 06/30/25 - - 03/31/25 - 5.22 12/31/24 - 6.76 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.84 12/31/24 - 8.21 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©